--- title: "U.S. stock market update: OSR Health down 22.25%: received a delisting warning from Nasdaq, uncertain outlook for appeal" type: "News" locale: "en" url: "https://longbridge.com/en/news/296509750.md" description: "OSR Health fell 22.25%; Moderna fell 20.28%, with a transaction volume of USD 6.352 billion; AbbVie fell 0.84%, with a transaction volume of USD 376 million; Amgen fell 2.08%, with a transaction volume of USD 218 million; Gilead Sciences fell 1.93%, with a market value of USD 179.5 billion" datetime: "2026-08-20T15:03:20.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/296509750.md) - [en](https://longbridge.com/en/news/296509750.md) - [zh-HK](https://longbridge.com/zh-HK/news/296509750.md) generator: "portal-rs" --- # U.S. stock market update: OSR Health down 22.25%: received a delisting warning from Nasdaq, uncertain outlook for appeal **U.S. Stock Market Midday Update** OSR Health fell 22.25%, with increased trading volume. Based on recent key news: 1. On August 19, Nasdaq notified OSR Health of its delisting due to failure to meet minimum bid requirements. This decision led to a decline in investor confidence and a significant drop in stock price. Source: SEC announcement 2. On August 20, OSR Health plans to appeal Nasdaq's delisting decision but acknowledges that the success of the appeal is not guaranteed, increasing risks to liquidity and investor confidence. Source: Company statement 3. On August 18, OSR Health disclosed a significant improvement in its medical loss ratio but expects a reduction in membership due to federal anti-fraud actions, which may impact financial performance. Source: Company announcement; the digital health industry faces compliance challenges. **Top Stocks by Industry Trading Volume** Moderna fell 20.28%. Based on recent news, 1. On August 19, Moderna's personalized cancer vaccine, co-developed with Merck, achieved positive results in Phase III clinical trials, significantly reducing the risk of melanoma recurrence, driving the stock price up. The vaccine is used in conjunction with Keytruda, and trial results showed a significant extension of patients' recurrence-free survival and reduced risk of cancer spread. Source: Caixin 2. On August 20, short sellers faced massive losses as Moderna's stock price surged, leading to nearly $5 billion in paper losses for short sellers. According to data from S3 Partners, Moderna's short ratio has decreased from 20% earlier this year to about 14%. Source: Bloomberg 3. On August 20, analysts adjusted their ratings on Moderna. RBC Capital raised the target price to $130 but maintained a sector perform rating. Bank of America upgraded its rating from sell to hold, believing the cancer vaccine is an important step in the company's diversification. Source: Barron’s; the biotechnology sector is performing strongly, with noticeable capital inflows. AbbVie fell 0.84%. Based on recent news, 1. On August 18, AbbVie announced a dividend of $0.38 per unit for the third quarter of 2026, with a payment date of August 20. This news had a limited impact on the stock price but reflects the company's stable dividend policy. 2. On August 14, AbbVie's Executive Vice President and Chief Business Strategy Officer Nicholas Donoghoe exercised stock options and sold 32,710 shares, reducing his direct holdings to 74,430 shares. This move may raise market concerns about executive confidence, affecting the stock price. 3. On August 20, AbbVie's revenue and profit fell significantly year-over-year, mainly due to the lack of major one-time transactions, but the company continues to maintain positive momentum in clinical trials and R&D. This news had a negative impact on the stock price. Industry competition is intensifying, and macroeconomic uncertainty is increasing Amgen fell by 2.08%. Based on recent key news: 4. On August 18, Amgen announced the termination of its research collaboration and licensing agreement with TScan Therapeutics. This move may impact Amgen's R&D pipeline, leading to market concerns about its future growth potential, resulting in a decline in stock price. 5. On August 17, Barclays raised Amgen's target price from $360 to $380 but maintained a neutral rating. Despite the target price increase, the neutral rating indicates analysts' cautious attitude towards Amgen's future performance, affecting investor confidence. 6. On August 17, AstraZeneca announced the official launch of tezepelumab injection in China. This drug was developed in collaboration with Amgen, and although this news is favorable for AstraZeneca, it failed to significantly boost Amgen's stock price. The competition in the pharmaceutical industry is intensifying, and R&D risks are increasing. **Stocks ranked among the top in industry market capitalization** Gilead Sciences fell by 1.93%. Based on recent key news: 1. On August 18, BMO Capital analyst Evan Seigerman reiterated a buy rating on Gilead Sciences with a target price of $174. Despite the positive rating from analysts, concerns about the company's future profitability remain, leading to stock price volatility. 2. On August 17, Gilead Sciences' Chief Communications and Corporate Affairs Officer Johanna Mercier exercised stock options, purchasing 25,000 shares and selling 28,000 shares. This insider trading activity raised market doubts about internal confidence in the company, affecting stock performance. 3. On August 18, a FactSet survey showed that analysts raised the median EPS estimate for Gilead Sciences for 2026 to -$0.45, but the adjustment in earnings expectations did not fully alleviate market concerns about the company's profit outlook, leading to pressure on the stock price. The competition in the biotechnology industry is intensifying, and profit pressures are increasing ### Related Stocks - [OSRH.US](https://longbridge.com/en/quote/OSRH.US.md) - [MRNA.US](https://longbridge.com/en/quote/MRNA.US.md) - [ABBV.US](https://longbridge.com/en/quote/ABBV.US.md) - [AMGN.US](https://longbridge.com/en/quote/AMGN.US.md) - [GILD.US](https://longbridge.com/en/quote/GILD.US.md) ## Related News & Research - [OSR Health: Preparing Our Appeal, Advancing Our Catalysts, Continuing Our Mission | OSRH Stock News](https://longbridge.com/en/news/296636382.md) - [OSR Health CEO says two subsidiaries draw out-licensing interest as Nasdaq bid deadline nears](https://longbridge.com/en/news/295540141.md) - [Moderna stock soars on cancer vaccine success](https://longbridge.com/en/news/296405393.md) - [If You Invested $1,000 In Moderna Stock at IPO, Here's How Much You'd Have Now](https://longbridge.com/en/news/296641626.md) - [Moderna’s 177% Surge Has Investors Asking What Comes Next](https://longbridge.com/en/news/296610623.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**